Chloroquine as a potential adjunctive therapy in tuberculosis

U. Matt, R. Müller, D. Müller, A. Stenzinger, A. Zinkernagel, A. Seelig, J. Nemeth (Zürich, Basel, Switzerland; Heidelberg, Germany)

Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Session: Mycobacterium tuberculosis infection: new therapeutic approaches
Session type: Oral Presentation
Number: 1896
Disease area: Respiratory infections

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
U. Matt, R. Müller, D. Müller, A. Stenzinger, A. Zinkernagel, A. Seelig, J. Nemeth (Zürich, Basel, Switzerland; Heidelberg, Germany). Chloroquine as a potential adjunctive therapy in tuberculosis. Eur Respir J 2014; 44: Suppl. 58, 1896

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015

Tuberculosis in patients receiving treatment of TNF-alpha inhibitors
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015


Impact of drug injection using on TB-AIDS treatment outcomes
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013

Clinical experience of clofazimine in the treatment of MDR-TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013


Statin use and the risk of tuberculosis: Data from 305,142 patients
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016


Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

Tuberculosis therapy
Source: International Congress 2016 – Historical landmarks in respiratory medicine: contributions from the UK
Year: 2016


Range of additional drug resistance of M.tuberculosis in XDR-TB patients
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016


Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Immuno-allergic reactions to antituberculosis treatment
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II
Year: 2013


Spreading of tuberculosis with extensive drug resistant MBTin Northwest region of Russia
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014

Tuberculosis and HIV infection in combination with multidrug resistant MBT on Northwest of Russia
Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease
Year: 2016

The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Trends of MBT drug resistance
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013


Is it necessary to give tuberculosis treatment daily throughout?
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014


Drug resistance among new TB cases in some Russian regions
Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children
Year: 2015


Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015


Side effects of tuberculosis treatment with fixed-dose combinations
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Confirmation of preclinical data on tioureidoiminomethylpyridinium perchlorate in treatment of MDR-TB
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


The pharmacogenomics in the personalization of isoniazid treatment of patients with tuberculosis
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016